GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (STU:NVV1) » Definitions » Total Equity

Novavax (STU:NVV1) Total Equity : €-797.7 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Novavax Total Equity?

Novavax's total equity for the quarter that ended in Mar. 2024 was €-797.7 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Novavax Total Equity Historical Data

The historical data trend for Novavax's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Total Equity Chart

Novavax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -167.42 515.57 -311.23 -598.57 -657.42

Novavax Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -836.47 -696.42 -635.61 -657.42 -797.72

Novavax Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Novavax's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=1648.298-2305.72
=-657.4

Novavax's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=1245.251-2042.969
=-797.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Total Equity Related Terms

Thank you for viewing the detailed overview of Novavax's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax (STU:NVV1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (STU:NVV1) » Definitions » Total Equity
Comparable Companies
ANAB WVE COGT NWBO ZYME KRRO OLMA MLYS LYEL IGMS OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
NVAX:USA NVAX:Mexico NVV1:Germany
Address
21 Firstfield Road, Gaithersburg, MD, USA, 20878
Website
https://www.novavax.com
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Novavax (STU:NVV1) Headlines

No Headlines